AstraZeneca today announced RECENTIN(TM) as the global trademark for AZD2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signalling inhibitor. AZD2171 is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback